In oncology, particularly in the therapy for NSCLC (NSCLC), osimertinib failure has become a significant concern.Osimertinib, being a targeted treatment, has shown remarkable efficacy in blocking the EGFR (EGFR) mutation, which is a common trigger of NSCLC (NSCLC).Despite its initial efficacy, a large percentage of patients experiences therapy failure.The aim of this article is to explore the basic challenges of osimertinib failure, emphasizing the factors causing its occurrence and the potential strategies for overcoming it.The primary reason for osimertinib failure is the emergence of resistance mechanisms.Resistance mechanisms arise from genetic…
